Clinical Trial

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife…

5 months ago

Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions

New venture harnesses multi-omic data and AI to develop the largest platform on complex chronic illnesses to drive breakthroughs in POTS,…

5 months ago

Carta Healthcare Honored as Silver Stevie® Award Winner in 2025 Stevie Awards for Technology Excellence

SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- Carta Healthcare, a leading provider of AI-powered clinical data abstraction, has been named…

5 months ago

VieCure Expands Community Oncology Care Network with Addition of Summit Cancer Centers

Multi-disciplinary cancer center joins VieCure's intelligent care ecosystem, bringing advanced precision oncology capabilities to the Pacific Northwest DENVER, CO /…

5 months ago

HMNC Brain Health Announces Phase 2 Results from OLIVE Trial in Major Depressive Disorder (MDD) with Genetically Guided Precision Approach

BH-200 (nelivaptan) achieved clinically meaningful reduction in depressive symptoms across the full study population (Difference between BH-200 and placebo in…

5 months ago

Revolo Accelerates Development of Orally Administered ‘1104 for Allergic Diseases

‘1104 sublingual formulation achieved extensive systemic exposure and demonstrated impact across measures of disease in additional preclinical studies in atopic…

5 months ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma,…

5 months ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Continued progress positions Company to report topline data for Phase 1 clinical trial of SENTI-202 before year-endSOUTH SAN FRANCISCO, Calif.,…

5 months ago

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing…

5 months ago

NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., Aug.…

5 months ago